SEC Filing Summary: Cerulean Pharma Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerulean Pharma Inc. on November 16, 2015. The filing serves to announce operational highlights for the three and nine months ended September 30, 2015, and outlines anticipated corporate and clinical milestones for the remainder of 2015 and 2016. The detailed financial and operational data is contained within a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is incorporated by reference but not fully reproduced in the provided text.
Material Changes
The filing indicates the announcement of operational highlights for the periods ended September 30, 2015. Specific quantitative changes versus prior periods are not disclosed in the main body of this Form 8-K.
Guidance, Outlook, and Risks
Management has provided anticipated corporate and clinical milestones for the remainder of 2015 and 2016. The filing includes a standard disclaimer stating that the information provided under Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 16, 2015) for specific revenue, cash burn, and liquidity figures.
- Verify the specific clinical milestones and timelines for 2015 and 2016 mentioned in the press release.
- Confirm the company's cash runway and funding status as of September 30, 2015, which are not explicitly stated in this summary text.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act.